Gilead Sciences promotes James Meyers
US biotech major Gilead Sciences (Nasdaq: GILD) has promoted James Meyers, who joined the company back in 1996.
Mr Myers now becomes executive vice president, worldwide commercial operations, with responsibility for commercial operations in North America, Europe and Japan. He will become an officer of the company and member of Gilead’s senior leadership team.
In his 20 years at Gilead, Mr Meyers has been instrumental in building out the company’s commercial operations in North America, including leading successful product launches in HIV, oncology, cardiovascular, respiratory and liver diseases. Prior to Gilead, Mr Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. He received his Bachelor's degree in economics from Boston College.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze